200 related articles for article (PubMed ID: 36518307)
41. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
42. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
[TBL] [Abstract][Full Text] [Related]
43. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
44. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
Mi JQ; Chen SJ; Zhou GB; Yan XJ; Chen Z
J Intern Med; 2015 Dec; 278(6):627-42. PubMed ID: 26058416
[TBL] [Abstract][Full Text] [Related]
45. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
[TBL] [Abstract][Full Text] [Related]
46. Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada.
Lachaine J; Mathurin K; Barakat S; Schuh AC
Hematol Oncol; 2015 Dec; 33(4):229-38. PubMed ID: 25424534
[TBL] [Abstract][Full Text] [Related]
47. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
48. Current standard treatment of adult acute promyelocytic leukaemia.
Lo-Coco F; Cicconi L; Breccia M
Br J Haematol; 2016 Mar; 172(6):841-54. PubMed ID: 26687281
[TBL] [Abstract][Full Text] [Related]
49. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
50. [Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
Wang J; Huang JB; Liu ZL; Zhang BH; Xu HG; Xue HM; Chen C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1605-1610. PubMed ID: 29262883
[TBL] [Abstract][Full Text] [Related]
51. Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia.
Helso SN; Roug AS; Mork M; Maksten EF; Severinsen MT
J Hematol; 2020 Sep; 9(3):89-92. PubMed ID: 32855758
[TBL] [Abstract][Full Text] [Related]
52. [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Lu Y; Li F; Mu Q; Meng H; Qian W; Tong H; Mai W; Pei R; Yu M; Zhao X; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):372-7. PubMed ID: 26031521
[TBL] [Abstract][Full Text] [Related]
53. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
[TBL] [Abstract][Full Text] [Related]
54. Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia:
Mohammadi Kanesbi M; Jarahi L; Keramati MR
Int J Hematol Oncol Stem Cell Res; 2020 Apr; 14(2):130-139. PubMed ID: 32461798
[TBL] [Abstract][Full Text] [Related]
55. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
56. Drug treatment options for acute promyelocytic leukemia.
Ferrara F; Molica M; Bernardi M
Expert Opin Pharmacother; 2022 Jan; 23(1):117-127. PubMed ID: 34348549
[TBL] [Abstract][Full Text] [Related]
57. ATRA+ATO combination in APL - A commentary on "evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades" by Teng-Fei et al.
Ortaboz D; Çetin MS; Cömert B; Eşkazan AE
Transl Oncol; 2023 Mar; 29():101620. PubMed ID: 36737174
[No Abstract] [Full Text] [Related]
58. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).
Lancet JE; Moseley AB; Coutre SE; DeAngelo DJ; Othus M; Tallman MS; Litzow MR; Komrokji RS; Erba HP; Appelbaum FR
Blood Adv; 2020 Apr; 4(8):1683-1689. PubMed ID: 32330241
[TBL] [Abstract][Full Text] [Related]
59. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Valenzuela M; Glorieux C; Stockis J; Sid B; Sandoval JM; Felipe KB; Kviecinski MR; Verrax J; Buc Calderon P
Br J Cancer; 2014 Aug; 111(5):874-82. PubMed ID: 25003661
[TBL] [Abstract][Full Text] [Related]
60. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
